IL320303A - טיפול באלרגיה לבוטנים עם ננו-חלקיקים עמידים - Google Patents

טיפול באלרגיה לבוטנים עם ננו-חלקיקים עמידים

Info

Publication number
IL320303A
IL320303A IL320303A IL32030325A IL320303A IL 320303 A IL320303 A IL 320303A IL 320303 A IL320303 A IL 320303A IL 32030325 A IL32030325 A IL 32030325A IL 320303 A IL320303 A IL 320303A
Authority
IL
Israel
Prior art keywords
administered
timp
ppe
nsaid
leukotriene modifier
Prior art date
Application number
IL320303A
Other languages
English (en)
Original Assignee
Cour Pharmaceuticals Dev Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cour Pharmaceuticals Dev Company Inc filed Critical Cour Pharmaceuticals Dev Company Inc
Publication of IL320303A publication Critical patent/IL320303A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL320303A 2022-10-19 2023-10-19 טיפול באלרגיה לבוטנים עם ננו-חלקיקים עמידים IL320303A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263380173P 2022-10-19 2022-10-19
US202363486812P 2023-02-24 2023-02-24
PCT/US2023/077287 WO2024086706A1 (en) 2022-10-19 2023-10-19 Treatment of peanut allergy with tolerizing nanoparticles

Publications (1)

Publication Number Publication Date
IL320303A true IL320303A (he) 2025-06-01

Family

ID=88874653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320303A IL320303A (he) 2022-10-19 2023-10-19 טיפול באלרגיה לבוטנים עם ננו-חלקיקים עמידים

Country Status (9)

Country Link
EP (1) EP4604999A1 (he)
JP (1) JP2025536294A (he)
KR (1) KR20250080899A (he)
CN (1) CN120282796A (he)
AU (1) AU2023364203A1 (he)
IL (1) IL320303A (he)
MX (1) MX2025004548A (he)
TW (1) TW202430207A (he)
WO (1) WO2024086706A1 (he)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013131925A1 (en) 2012-03-06 2013-09-12 Highlife Sas Treatment catheter member with encircling function
KR102233251B1 (ko) * 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
CN105555301B (zh) 2013-08-13 2021-04-16 西北大学 肽缀合颗粒
EP3393514A4 (en) 2015-12-23 2019-08-14 Cour Pharmaceuticals Development Company Inc. KOVALENTE POLYMER ANTIGEN CONJUGATED PARTICLES
JP6904959B2 (ja) 2016-01-04 2021-07-21 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 結合エピトープを含有する融合タンパク質を封入する粒子
MX2023012257A (es) 2021-04-16 2024-01-08 Cour Pharmaceuticals Dev Company Inc Método de rastreo del mantenimiento de la inmunotolerancia.
CN117813111A (zh) * 2021-04-16 2024-04-02 库尔制药开发公司 用耐受纳米粒子治疗花生过敏

Also Published As

Publication number Publication date
WO2024086706A1 (en) 2024-04-25
KR20250080899A (ko) 2025-06-05
CN120282796A (zh) 2025-07-08
TW202430207A (zh) 2024-08-01
EP4604999A1 (en) 2025-08-27
AU2023364203A1 (en) 2025-05-15
JP2025536294A (ja) 2025-11-05
MX2025004548A (es) 2025-06-02

Similar Documents

Publication Publication Date Title
US11344545B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
DK2303287T3 (en) Antiallergic marine biopolymers
JP2024174927A5 (he)
US9993512B2 (en) Use of escin
JPH05506007A (ja) ２’３’―ジデオキシイノシンによるヒトのレトロウィルス感染症の治療
JP2009529502A5 (he)
EP3348273B1 (en) Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
WO2014164285A2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
Lane A steroid sparing effect of ketotifen in steroid‐dependent asthmatics
JP2016512247A5 (he)
Carson et al. Severe rhinitis medicamentosa successfully treated with Rhinolight® endonasal UV phototherapy
CN114404409A (zh) 一种可治疗疼痛的药物组合及其应用
JP2023527926A5 (he)
RU2065748C1 (ru) Способ лечения хронических стафилодермий
JP2023517295A5 (he)
CN101155581A (zh) 用于单纯疱疹的药物和治疗
CN109528708A (zh) 山奈酚在制备治疗鼻炎药物中的应用
Strauss Complications from Flu–an unnecessary evil!
Cho et al. Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms
Strauss Complications from Flu-an unnecessary evil! How to treat and manage patients suffering from influenza in order to prevent unnecessary complications and adverse outcomes.
CN111467357A (zh) 一种药物组合物及其制备方法和用途
Khangura Considering the integration of cannabis into conventional chronic pain management strategies
OA20662A (fr) Médicament à base d'extraits de six plantes indiqué pour le traitement du covid-19.
JPH11236402A (ja) 新規多糖体及び、該多糖体の抗ウイルス剤並びにアジュバント剤
Upendrababu Red man syndrome